[11C]-L-methionine Positron Emission Tomography in the Management of Children and Young Adults with Brain Tumors

Overview

Journal J Neurooncol

Publisher Springer

Date 2009 Jul 4

PMID 19575148

Citations 25

Authors

Norbert Galldiks

Lutz W Kracht

Frank Berthold

Hrvoje Miletic

Johannes C Klein

Karl Herholz

Andreas H Jacobs

Wolf-Dieter Heiss

Affiliations

Soon will be listed here.

Abstract

Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm. Due to radiation exposure, long scan acquisition time, and the need for sedation in young children MET-PET studies should be restricted to this group of patients when a decision for further therapy is not possible from routine diagnostic procedures alone, e.g., structural imaging. We investigated the diagnostic accuracy of MET-PET for the differentiation between tumorous and non-tumorous lesions in this group of patients. Forty eight MET-PET scans from 39 patients aged from 2 to 21 years (mean 15 +/- 5.0 years) were analyzed. The MET tumor-uptake relative to a corresponding control region was calculated. A receiver operating characteristic (ROC) was performed to determine the MET-uptake value that best distinguishes tumorous from non-tumorous brain lesions. A differentiation between tumorous (n = 39) and non-tumorous brain lesions (n = 9) was possible at a threshold of 1.48 of relative MET-uptake with a sensitivity of 83% and a specificity of 92%, respectively. A differentiation between high grade malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and low grade tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible. There was a significant difference in MET-uptake between the histologically homogeneous subgroups of astrocytoma WHO grade II and anaplastic astrocytoma WHO grade III (P = 0.02). MET-PET might be a useful tool to differentiate tumorous from non-tumorous lesions in children and young adults when a decision for further therapy is difficult or impossible from routine structural imaging procedures alone.

Citing Articles

Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0.

Piccardo A, Albert N, Borgwardt L, Fahey F, Hargrave D, Galldiks N Eur J Nucl Med Mol Imaging. 2022; 49(11):3852-3869.

PMID: 35536420 PMC: 9399211. DOI: 10.1007/s00259-022-05817-6.

Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.

Marner L, Lundemann M, Sehested A, Nysom K, Borgwardt L, Mathiasen R Neuro Oncol. 2021; 23(12):2107-2116.

PMID: 33864083 PMC: 8643444. DOI: 10.1093/neuonc/noab096.

Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity.

Lu W, Saha A, Yan W, Garrison K, Lamb C, Pandey R Proc Natl Acad Sci U S A. 2020; 117(23):13000-13011.

PMID: 32434918 PMC: 7293657. DOI: 10.1073/pnas.1917362117.

The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A C-MET PET Study.

Kudulaiti N, Zhang H, Qiu T, Lu J, Aibaidula A, Zhang Z Mol Imaging. 2020; 18:1536012119894087.

PMID: 31889470 PMC: 6997723. DOI: 10.1177/1536012119894087.

F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

Gauvain K, Ponisio M, Barone A, Grimaldi M, Parent E, Leeds H Neurooncol Pract. 2018; 5(1):28-36.

PMID: 29692922 PMC: 5909807. DOI: 10.1093/nop/npx008.

References

Chung J, Kim Y, Kim S, Lee Y, Paek S, Yeo J . Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002; 29(2):176-82. DOI: 10.1007/s00259-001-0690-4. View

Herholz K, Kracht L, Heiss W . Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging. 2003; 13(3):269-71. View

Utriainen M, Metsahonkala L, Salmi T, Utriainen T, Kalimo H, Pihko H . Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer. 2002; 95(6):1376-86. DOI: 10.1002/cncr.10798. View

Bergstrom M, Collins V, Ehrin E, Ericson K, Eriksson L, Greitz T . Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr. 1983; 7(6):1062-6. DOI: 10.1097/00004728-198312000-00022. View

Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U . The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994; 18(1):110-8. View

Ruotsalainen U, Eronen E, Kinnala A, Bergman J, Haaparanta M, Teras M . Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996; 37(2):387-93. View

Kracht L, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A . Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003; 30(6):868-73. DOI: 10.1007/s00259-003-1148-7. View

Jacobs A, DITTMAR C, Winkeler A, Garlip G, Heiss W . Molecular imaging of gliomas. Mol Imaging. 2003; 1(4):309-35. DOI: 10.1162/15353500200221392. View

Langen K, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen H . Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. J Nucl Med. 2000; 41(7):1250-5. View

10.

Pirotte B, Goldman S, Salzberg S, Wikler D, David P, Vandesteene A . Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg. 2003; 38(3):146-55. DOI: 10.1159/000068820. View

11.

Mosskin M, von Holst H, Bergstrom M, Collins V, Eriksson L, Johnstrom P . Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol. 1987; 28(6):673-81. View

12.

Jager P, Vaalburg W, Pruim J, De Vries E, Langen K, Piers D . Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001; 42(3):432-45. View

13.

Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss W . Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr. 1992; 16(5):804-13. DOI: 10.1097/00004728-199209000-00024. View

14.

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

15.

Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T . Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 2000; 22(4):210-4. DOI: 10.1007/s101430050018. View

16.

Galldiks N, Burghaus L, Vollmar S, Cizek J, Impekoven P, Thomas A . Novel neuroimaging findings in a patient with cerebral Whipple's disease: a magnetic resonance imaging and positron emission tomography study. J Neuroimaging. 2004; 14(4):372-6. DOI: 10.1177/1051228404267994. View

17.

Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus R . 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998; 50(5):1316-22. DOI: 10.1212/wnl.50.5.1316. View

18.

Galldiks N, Kracht L, Burghaus L, Thomas A, Jacobs A, Heiss W . Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006; 33(5):516-24. DOI: 10.1007/s00259-005-0002-5. View

19.

Borgwardt L, Larsen H, Pedersen K, Hojgaard L . Practical use and implementation of PET in children in a hospital PET centre. Eur J Nucl Med Mol Imaging. 2003; 30(10):1389-97. DOI: 10.1007/s00259-003-1263-5. View

20.

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View